Websites Selling Compounded GLP-1 RAs Often Misinform Consumers

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 22, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 21, 2025 -- Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration approval, according to a research letter published online Jan. 17 in JAMA Health Forum.

Ashwin K. Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide, tirzepatide, and liraglutide.

The researchers found that 98 unique websites sold any GLP-1 RA during the study period; the analysis included 79 of these websites that sold compounded GLP-1 RAs or a prescription for compounded medications. All 79 websites sold compounded semaglutide and 72.2 and 3.8 percent sold compounded tirzepatide and liraglutide, respectively. Overall, 52 websites featured a mark of certification; 50 displayed LegitScript certification. Two websites required a prior prescription for compounded GLP-1 RAs and did not provide a prescription. Eleven and seven of the websites did not disclose GLP-1 RAs were compounded and referred to compounded medications as generic, respectively. Thirty-four of the websites stated that the compounded medications were not FDA approved, while 29 stated or implied that these drugs were approved. Adverse effects, warnings and precautions, and contraindications of compounded GLP-1 RAs were not reported by 39 websites (49.4 percent), while 32 sites advertised an efficacy claim not in the authorized label of the FDA-approved branded GLP-1 RA.

"Enhanced regulatory guidance and oversight are needed to clarify criteria for 'truthful, non-misleading, and accurate' advertising to ensure consumers are informed of the risks and benefits of compounded GLP-1 RAs and other compounded medications," the authors write.

Several authors disclosed ties to industry.

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-23 00:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords